The present analysis proposes two candidates following the molecular docking study based on the highest potential binding to the target proteins impacting glaucoma, ROCK1 and ROCK2, representing a preliminary step in drug design studies, a step that needs to be confirmed by extensive computational studies (i.e., molecular dynamics, network pharmacology), in vivo in animal models, and clinical studies in different phases where efficacy and safety profiles are evaluated. The gene discussed is ROCK2; the disease is glaucoma.